Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer

2021 ◽  
pp. a037838
Author(s):  
Gina M. DeNicola ◽  
David B. Shackelford
Keyword(s):  
Lung Cancer ◽  
Metabolic Phenotypes

The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

1989 ◽  
Vol 6 (4) ◽  
pp. 517-524 ◽  
Author(s):  
Neil Caporaso ◽  
Linda Williams Pickle ◽  
Sherri Bale ◽  
Riad Ayesh ◽  
Martin Hetzel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Lung Cancer Risk ◽  
Metabolic Phenotypes

Metabolic reprograming of antioxidant defense: a precision medicine perspective for radiotherapy of lung cancer?

2021 ◽  
Author(s):  
Johann Matschke ◽  
Safa Larafa ◽  
Verena Jendrossek
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Antioxidant Defense ◽  
Cancer Metabolism ◽  
Somatic Mutations ◽  
Molecular Subtypes ◽  
Predictive Biomarkers ◽  
Metabolic Phenotype ◽  
Molecular Heterogeneity ◽  
Metabolic Phenotypes

Radiotherapy plays a key role in the management of lung cancer patients in curative and palliative settings. Traditionally, radiotherapy was either given alone or in combination with surgery, classical cytotoxic chemotherapy, or both. Technical and physical innovations achieved during the last two decades have helped to enhance the accuracy of radiotherapy dose delivery and have facilitated geometric radiotherapy individualization. Furthermore, multimodal combinations with molecularly tailored drugs or immunotherapy yielded promising survival benefits in selected patients. Yet high locoregional failure rates and frequent development of metastases still limit the patient outcome. One major obstacle to successful treatment is the high molecular heterogeneity observed in lung cancer. So far, clinical radiotherapy does not routinely use the knowledge on molecular subtypes with regard to therapy individualization and predictive biomarkers are missing. Herein, altered cancer metabolism has attracted novel attention during recent years as it promotes tumor growth and progression as well as resistance to anticancer therapies. The present perspective will exemplarily highlight how clinically relevant molecular subtypes defined by co-occurring somatic mutations in KRAS-driven lung cancer impact the metabolic phenotype of cancer cells, how the metabolic phenotype supports intrinsic radioresistance by the improved antioxidant defense, and also discuss potential subtype-specific actionable metabolic vulnerabilities. Understanding metabolic phenotypes of radioresistance and metabolic bottlenecks of cancer cells undergoing radiotherapy in a cancer-specific context will offer largely unexploited future avenues for biological individualization and optimization of radiotherapy. Transcriptional profiles will provide additional benefit in defining metabolic phenotypes associated with radioresistance, particularly in cases, where such dependencies cannot be identified by specific somatic mutations.

Comment: predictability of survival in the individual patient with lung cancer

JAMA ◽  
1966 ◽  
Vol 195 (12) ◽  
pp. 1036-1037 ◽  
Author(s):  
P. Rubin
Keyword(s):  
Lung Cancer ◽  
The Individual

The question of irradiation therapy in lung cancer

JAMA ◽  
1966 ◽  
Vol 195 (6) ◽  
pp. 471-475 ◽  
Author(s):  
M. J. Krant
Keyword(s):  
Lung Cancer ◽  
Irradiation Therapy

Surgery for Lung Cancer and the Consequences for the Swallow

2016 ◽  
Vol 1 (13) ◽  
pp. 162-168
Author(s):  
Pippa Hales ◽  
Corinne Mossey-Gaston
Keyword(s):  
Lung Cancer ◽  
Treatment Options ◽  
Vocal Cord Palsy ◽  
Subsequent Treatment ◽  
Physiological Reserve ◽  
Palliative Phase ◽  
And Function ◽  
The Impact ◽  
Swallow Function

Lung cancer is one of the most commonly diagnosed cancers across Northern America and Europe. Treatment options offered are dependent on the type of cancer, the location of the tumor, the staging, and the overall health of the person. When surgery for lung cancer is offered, difficulty swallowing is a potential complication that can have several influencing factors. Surgical interaction with the recurrent laryngeal nerve (RLN) can lead to unilateral vocal cord palsy, altering swallow function and safety. Understanding whether the RLN has been preserved, damaged, or sacrificed is integral to understanding the effect on the swallow and the subsequent treatment options available. There is also the risk of post-surgical reduction of physiological reserve, which can reduce the strength and function of the swallow in addition to any surgery specific complications. As lung cancer has a limited prognosis, the clinician must also factor in the palliative phase, as this can further increase the burden of an already compromised swallow. By understanding the surgery and the implications this may have for the swallow, there is the potential to reduce the impact of post-surgical complications and so improve quality of life (QOL) for people with lung cancer.

Use of Tumor Markers in Lung Cancer

1994 ◽  
Vol 8 (3) ◽  
pp. 507-532 ◽  
Author(s):  
Gary M. Strauss ◽  
Arthur T. Skarin
Keyword(s):  
Lung Cancer ◽  
Tumor Markers

Lung cancer 2

2001 ◽  
Vol 37 ◽  
pp. 152-154 ◽  
Keyword(s):  
Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document